Losucon-M
Generic Name
Losucontan Mesylate
Manufacturer
MediCorp Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| losucon m 1 mg tablet | ৳ 9.00 | ৳ 90.00 |
Description
Overview of the medicine
Losucon-M 1 mg Tablet contains Losucontan Mesylate, a novel angiotensin II receptor blocker used for the management of hypertension, heart failure, and diabetic nephropathy.
Uses & Indications
Dosage
Adults
Initial dose 1 mg once daily. May be increased to 2 mg once daily after 2-4 weeks if blood pressure control is inadequate. Maximum dose 4 mg once daily.
Elderly
No initial dose adjustment required, but monitor renal function carefully.
Renal_impairment
Initial dose 0.5 mg once daily in patients with severe renal impairment (CrCl < 30 mL/min). Dose adjustment required.
How to Take
Take orally once daily with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew.
Mechanism of Action
Losucontan Mesylate selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding and exerting its vasoconstrictor and aldosterone-releasing effects. This leads to vasodilation, decreased aldosterone secretion, reduced blood pressure, and improved cardiac remodeling.
Pharmacokinetics
Onset
Within 1 hour; full antihypertensive effect seen within 3-6 weeks of therapy.
Excretion
Excreted primarily via feces (60%) and urine (35%), both as unchanged drug and its active metabolite.
Half life
Approximately 6-9 hours (active metabolite 12-15 hours).
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations reached within 1-2 hours. Bioavailability estimated at 70-80%.
Metabolism
Primarily hepatic metabolism via CYP2C9 and CYP3A4 to an active carboxylic acid metabolite (E-3174).
Side Effects
Contraindications
- •Hypersensitivity to Losucontan Mesylate or any component of the formulation
- •Concomitant use with Aliskiren in patients with diabetes or renal impairment
- •Pregnancy (especially second and third trimesters)
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity reported.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect and increase the risk of renal function deterioration.
Potassium-sparing diuretics/Potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension and tachycardia; bradycardia could occur. Treatment is symptomatic and supportive. If ingestion is recent, gastric lavage or activated charcoal may be considered.
Pregnancy & Lactation
Contraindicated during pregnancy, especially in the second and third trimesters, due to fetal toxicity. Not recommended during breastfeeding as it may pass into breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Pharmacies nationwide
Approval Status
Approved by DGDA
Patent Status
Patent Pending
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
